Skip to main content
Top
Published in:

01-02-2025 | Lung Cancer | Review Article Free for a limited time

Concomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review

Authors: Han Deng, Junxiang Zhou, Zhixi Liu, Lu Huang, Yanru Gu, Peng Chen, Hongtao Xiao

Published in: Medical Oncology | Issue 2/2025

Login to get access

Abstract

In the past decade, a variety of immune checkpoint inhibitors (ICIs) are currently approved for lung cancer in the world. As a new therapeutic approach, ICIs have shown significant clinical benefits in the first-line or second-line treatment for advanced lung cancer, improving the survival and quality of life of patients. Patients need to take multiple drugs in the meantime due to their own disease or side effects during treatment. In view of drug interactions, concomitant medications have a positive or negative impact on the prognosis of lung cancer patients. In this review, we reviewed the effects of multiple drugs on the prognosis of patients with lung cancer taking ICIs. Several studies indicate that antibiotics, proton pump inhibitors (PPIs), corticosteroids, and opioid analgesics can decrease the efficacy of ICIs. Aspirin and bone-targeting drugs can enhance the efficacy of ICIs and improve the survival rate. The effects of metformin (MET), renin–angiotensin–aldosterone system inhibitors (RASI), nonsteroidal anti-inflammatory drug (NSAIDS) (except aspirin), and statins on ICIs are controversial. Future research should further explore the effects of these concomitant medications on ICIs and develop personalized prescriptions based on the specific needs of patients.
Literature
2.
go back to reference Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. Embo J. 1992;11(11):3887–95.PubMedPubMedCentral Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. Embo J. 1992;11(11):3887–95.PubMedPubMedCentral
3.
go back to reference Rezayi M, Hosseini A. Structure of PD1 and its mechanism in the treatment of autoimmune diseases. Cell Biochem Funct. 2023;41(7):726–37.PubMed Rezayi M, Hosseini A. Structure of PD1 and its mechanism in the treatment of autoimmune diseases. Cell Biochem Funct. 2023;41(7):726–37.PubMed
4.
go back to reference Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.PubMedPubMedCentral Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.PubMedPubMedCentral
5.
go back to reference Shen D-D, Bi Y-P, Pang J-R, Zhao L-J, Zhao L-F, Gao Y, Wang B, Liu H-M, Liu Y, Wang N, Zheng Y-C, Liu H-M. Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cell Mol Life Sci. 2022;79(8):413.PubMedPubMedCentral Shen D-D, Bi Y-P, Pang J-R, Zhao L-J, Zhao L-F, Gao Y, Wang B, Liu H-M, Liu Y, Wang N, Zheng Y-C, Liu H-M. Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cell Mol Life Sci. 2022;79(8):413.PubMedPubMedCentral
6.
go back to reference Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, Lv C, Zhou Y, Xia Y, Tang W. Various uses of PD1/PD-L1 inhibitor in oncology: opportunities and challenges. Front Oncol. 2021;11: 771335.PubMedPubMedCentral Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, Lv C, Zhou Y, Xia Y, Tang W. Various uses of PD1/PD-L1 inhibitor in oncology: opportunities and challenges. Front Oncol. 2021;11: 771335.PubMedPubMedCentral
7.
8.
go back to reference Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily–CTLA-4. Nature. 1987;328(6127):267–70.PubMed Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily–CTLA-4. Nature. 1987;328(6127):267–70.PubMed
9.
go back to reference Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O’Byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–60.PubMedPubMedCentral Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O’Byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–60.PubMedPubMedCentral
10.
go back to reference Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker MG, Nigro O, Tanda E, Russo A. Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol. 2019;142:26–34.PubMed Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker MG, Nigro O, Tanda E, Russo A. Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol. 2019;142:26–34.PubMed
11.
go back to reference Sieber B, Strauss J, Li ZH, Gatti-Mays ME. Concomitant medication effects on immune checkpoint inhibitor efficacy and toxicity. Front Oncol. 2022;12:836934.PubMedPubMedCentral Sieber B, Strauss J, Li ZH, Gatti-Mays ME. Concomitant medication effects on immune checkpoint inhibitor efficacy and toxicity. Front Oncol. 2022;12:836934.PubMedPubMedCentral
12.
go back to reference Cook MA, Wright GD. The past, present, and future of antibiotics. Sci Transl Med. 2022;14(657):eabo7793.PubMed Cook MA, Wright GD. The past, present, and future of antibiotics. Sci Transl Med. 2022;14(657):eabo7793.PubMed
13.
go back to reference Araji G, Maamari J, Ahmad FA, Zareef R, Chaftari P, Yeung SJ. The emerging role of the gut microbiome in the cancer response to immune checkpoint inhibitors: a narrative review. J Immunother Precis Oncol. 2022;5(1):13–25.PubMed Araji G, Maamari J, Ahmad FA, Zareef R, Chaftari P, Yeung SJ. The emerging role of the gut microbiome in the cancer response to immune checkpoint inhibitors: a narrative review. J Immunother Precis Oncol. 2022;5(1):13–25.PubMed
14.
go back to reference Swami U, Zakharia Y, Zhang J. Understanding microbiome effect on immune checkpoint inhibition in lung cancer: placing the puzzle pieces together. J Immunother. 2018;41(8):359–60.PubMed Swami U, Zakharia Y, Zhang J. Understanding microbiome effect on immune checkpoint inhibition in lung cancer: placing the puzzle pieces together. J Immunother. 2018;41(8):359–60.PubMed
15.
go back to reference Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (New York, NY). 2015;350(6264):1084–9. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (New York, NY). 2015;350(6264):1084–9.
16.
go back to reference Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist. 2019;25(1):55–63.PubMedPubMedCentral Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist. 2019;25(1):55–63.PubMedPubMedCentral
17.
go back to reference Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, Ren S, Chen X, Zhou C. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10–7.PubMed Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, Ren S, Chen X, Zhou C. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10–7.PubMed
18.
go back to reference Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–8.PubMedPubMedCentral Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–8.PubMedPubMedCentral
19.
go back to reference Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670.PubMedPubMedCentral Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670.PubMedPubMedCentral
20.
go back to reference Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall’Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021;32(11):1391–9.PubMed Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall’Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021;32(11):1391–9.PubMed
21.
go back to reference Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D’Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele DT, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9(4):e002421.PubMedPubMedCentral Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D’Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele DT, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9(4):e002421.PubMedPubMedCentral
22.
go back to reference Qiu H, Ma Q-G, Chen X-T, Wen X, Zhang N, Liu W-M, Wang T-T, Zhang L-Z. Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Am J Cancer Res. 2022;12(7):3175–84.PubMedPubMedCentral Qiu H, Ma Q-G, Chen X-T, Wen X, Zhang N, Liu W-M, Wang T-T, Zhang L-Z. Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Am J Cancer Res. 2022;12(7):3175–84.PubMedPubMedCentral
23.
go back to reference Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021;149:73–81.PubMed Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021;149:73–81.PubMed
24.
go back to reference Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety—a narrative review. Dig Liver Dis. 2020;52(8):842–52.PubMed Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety—a narrative review. Dig Liver Dis. 2020;52(8):842–52.PubMed
25.
go back to reference Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710.PubMed Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710.PubMed
26.
go back to reference Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer. Jama Netw Open. 2023;6(7):e2322915.PubMedPubMedCentral Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer. Jama Netw Open. 2023;6(7):e2322915.PubMedPubMedCentral
27.
go back to reference Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525–31.PubMed Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525–31.PubMed
28.
go back to reference Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2022;126(1):42–7.PubMed Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2022;126(1):42–7.PubMed
29.
go back to reference Peng KN, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother. 2022;56(4):377–86.PubMed Peng KN, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother. 2022;56(4):377–86.PubMed
30.
go back to reference Hopkins AM, Badaoui S, Kichenadasse G, Karapetis CS, McKinnon RA, Rowland A, Sorich MJ. Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials. J Thorac Oncol. 2022;17(6):758–67.PubMed Hopkins AM, Badaoui S, Kichenadasse G, Karapetis CS, McKinnon RA, Rowland A, Sorich MJ. Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials. J Thorac Oncol. 2022;17(6):758–67.PubMed
31.
go back to reference Qin B-D, Jiao X-D, Zhou X-C, Shi B, Wang J, Liu K, Wu Y, Ling Y, Zang Y-S. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. OncoImmunology. 2021;10(1):1929727.PubMedPubMedCentral Qin B-D, Jiao X-D, Zhou X-C, Shi B, Wang J, Liu K, Wu Y, Ling Y, Zang Y-S. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. OncoImmunology. 2021;10(1):1929727.PubMedPubMedCentral
32.
go back to reference Dar S, Merza N, Rahim M, Qatani A, Varughese T, Mohammad A, Masood F, Reza F, Almas TS, Ellahi A, Ligresti R. Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Ann Med Surg. 2022;78:103752. Dar S, Merza N, Rahim M, Qatani A, Varughese T, Mohammad A, Masood F, Reza F, Almas TS, Ellahi A, Ligresti R. Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Ann Med Surg. 2022;78:103752.
33.
go back to reference Prattichizzo F, Giuliani A, Mensa E, Sabbatinelli J, De Nigris V, Rippo MR, La Sala L, Procopio AD, Olivieri F, Ceriello A. Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Res Rev. 2018;48:87–98.PubMed Prattichizzo F, Giuliani A, Mensa E, Sabbatinelli J, De Nigris V, Rippo MR, La Sala L, Procopio AD, Olivieri F, Ceriello A. Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Res Rev. 2018;48:87–98.PubMed
34.
go back to reference Wang G, Xu M, Xie M. Research advance in anti-lung cancer mechanism of metformin. Zhongguo Fei Ai Za Zhi. 2020;23(4):282–5.PubMed Wang G, Xu M, Xie M. Research advance in anti-lung cancer mechanism of metformin. Zhongguo Fei Ai Za Zhi. 2020;23(4):282–5.PubMed
35.
go back to reference Yang J, Kim SH, Jung EH, Kim S-A, Suh KJ, Lee JY, Kim J-W, Kim JW, Lee J-O, Kim YJ, Lee K-W, Kim JH, Bang S-M, Lee JS. The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer. 2023;14(1):52–60.PubMed Yang J, Kim SH, Jung EH, Kim S-A, Suh KJ, Lee JY, Kim J-W, Kim JW, Lee J-O, Kim YJ, Lee K-W, Kim JH, Bang S-M, Lee JS. The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer. 2023;14(1):52–60.PubMed
36.
go back to reference Afzal MZ, Dragnev K, Sarwar T, Shirai K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manage. 2019;8(2):LMT11. Afzal MZ, Dragnev K, Sarwar T, Shirai K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manage. 2019;8(2):LMT11.
37.
go back to reference Pietras R, Xu H, Hu X, Matheny C, Sandler A, Patel M. Retrospective descriptive analysis of metformin with atezolizumab in advanced non-small cell lung cancer in the OAK trial. J Thorac Oncol. 2018;13(10):S538–9. Pietras R, Xu H, Hu X, Matheny C, Sandler A, Patel M. Retrospective descriptive analysis of metformin with atezolizumab in advanced non-small cell lung cancer in the OAK trial. J Thorac Oncol. 2018;13(10):S538–9.
38.
go back to reference Jacobi O, Landman Y, Reinhorn D, Icht O, Sternschuss M, Rotem O, Finkel I, Allen AM, Dudnik E, Goldstein DA, Zer A. The relationship of diabetes mellitus to efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Oncology. 2021;99(9):555–61.PubMed Jacobi O, Landman Y, Reinhorn D, Icht O, Sternschuss M, Rotem O, Finkel I, Allen AM, Dudnik E, Goldstein DA, Zer A. The relationship of diabetes mellitus to efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Oncology. 2021;99(9):555–61.PubMed
39.
go back to reference Luo X, Chen X, Wang L, Yang B, Cai S. Metformin adjunct with antineoplastic agents for the treatment of lung cancer: a meta-analysis of randomized controlled trials and observational cohort studies. Front Pharmacol. 2021;12:639016.PubMedPubMedCentral Luo X, Chen X, Wang L, Yang B, Cai S. Metformin adjunct with antineoplastic agents for the treatment of lung cancer: a meta-analysis of randomized controlled trials and observational cohort studies. Front Pharmacol. 2021;12:639016.PubMedPubMedCentral
40.
go back to reference Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.PubMed Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.PubMed
41.
go back to reference Marcianò G, Palleria C, Casarella A, Rania V, Basile E, Catarisano L, Vocca C, Bianco L, Pelaia C, Cione E, D’Agostino B, Citraro R, De Sarro G, Gallelli L. Effect of statins on lung cancer molecular pathways: a possible therapeutic role. Pharmaceuticals (Basel, Switzerland). 2022;15(5):589.PubMed Marcianò G, Palleria C, Casarella A, Rania V, Basile E, Catarisano L, Vocca C, Bianco L, Pelaia C, Cione E, D’Agostino B, Citraro R, De Sarro G, Gallelli L. Effect of statins on lung cancer molecular pathways: a possible therapeutic role. Pharmaceuticals (Basel, Switzerland). 2022;15(5):589.PubMed
42.
go back to reference Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.PubMedPubMedCentral Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.PubMedPubMedCentral
43.
go back to reference Nguyen PA, Chang CC, Galvin CJ, Wang YC, An SY, Huang CW, Wang YH, Hsu MH, Li YC, Yang HC. Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: a cancer registry cohort study in Taiwan. Cancer Sci. 2020;111(8):2965–73.PubMedPubMedCentral Nguyen PA, Chang CC, Galvin CJ, Wang YC, An SY, Huang CW, Wang YH, Hsu MH, Li YC, Yang HC. Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: a cancer registry cohort study in Taiwan. Cancer Sci. 2020;111(8):2965–73.PubMedPubMedCentral
44.
go back to reference Cantini L, Pecci F, Hurkmans DP, Belderbos RA, Lanese A, Copparoni C, Aerts S, Cornelissen R, Dumoulin DW, Fiordoliva I, Rinaldi S, Aerts JGJV, Berardi R. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. Eur J Cancer. 2021;144:41–8.PubMed Cantini L, Pecci F, Hurkmans DP, Belderbos RA, Lanese A, Copparoni C, Aerts S, Cornelissen R, Dumoulin DW, Fiordoliva I, Rinaldi S, Aerts JGJV, Berardi R. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. Eur J Cancer. 2021;144:41–8.PubMed
45.
go back to reference Mao W, Cai Y, Chen D, Jiang G, Xu Y, Chen R, Wang F, Wang X, Zheng M, Zhao X, Mei J. Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non–small cell lung cancer. JCI Insight. 2022;7(18):e161940.PubMedPubMedCentral Mao W, Cai Y, Chen D, Jiang G, Xu Y, Chen R, Wang F, Wang X, Zheng M, Zhao X, Mei J. Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non–small cell lung cancer. JCI Insight. 2022;7(18):e161940.PubMedPubMedCentral
46.
go back to reference Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thorac Cancer. 2021;12(13):1983–94.PubMedPubMedCentral Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thorac Cancer. 2021;12(13):1983–94.PubMedPubMedCentral
47.
go back to reference Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. BMC Cancer. 2022;22(1):503.PubMedPubMedCentral Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. BMC Cancer. 2022;22(1):503.PubMedPubMedCentral
48.
go back to reference Omori M, Okuma Y, Hakozaki T, Hosomi Y. Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: an observational study. Mol Clin Oncol. 2019;10(1):137–43.PubMed Omori M, Okuma Y, Hakozaki T, Hosomi Y. Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: an observational study. Mol Clin Oncol. 2019;10(1):137–43.PubMed
49.
go back to reference Filetti M, Rossi A, Piras M, Salimbeni BT, Rizzo F, Giusti R. Statins and immunotherapy: togetherness makes strength the potential effect of statins on immunotherapy for NSCLC. Ann Oncol. 2020;31:S1449–S1449. Filetti M, Rossi A, Piras M, Salimbeni BT, Rizzo F, Giusti R. Statins and immunotherapy: togetherness makes strength the potential effect of statins on immunotherapy for NSCLC. Ann Oncol. 2020;31:S1449–S1449.
50.
go back to reference Svaton M, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Jakubikova L, Cernovska M, Hrnciarik M, Jirousek M, Krejci J, Krejci D, Bilek O, Blazek J, Hurdalkova K, Barinova M, Melichar B. Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer. Anticancer Res. 2020;40(4):2209–17.PubMed Svaton M, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Jakubikova L, Cernovska M, Hrnciarik M, Jirousek M, Krejci J, Krejci D, Bilek O, Blazek J, Hurdalkova K, Barinova M, Melichar B. Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer. Anticancer Res. 2020;40(4):2209–17.PubMed
51.
go back to reference Zhang L, Wang H, Tian J, Sui L, Chen X, Niu B. Concomitant statins and the survival of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis. Int J Clin Pract. 2022;2022:1–10. Zhang L, Wang H, Tian J, Sui L, Chen X, Niu B. Concomitant statins and the survival of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis. Int J Clin Pract. 2022;2022:1–10.
52.
go back to reference Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thoracic Cancer. 2021;12(13):1983–94.PubMedPubMedCentral Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thoracic Cancer. 2021;12(13):1983–94.PubMedPubMedCentral
53.
go back to reference Yang J, Yang X, Gao L, Zhang J, Yi C, Huang Y. The role of the renin-angiotensin system inhibitors in malignancy: a review. Am J Cancer Res. 2021;11(3):884–97.PubMedPubMedCentral Yang J, Yang X, Gao L, Zhang J, Yi C, Huang Y. The role of the renin-angiotensin system inhibitors in malignancy: a review. Am J Cancer Res. 2021;11(3):884–97.PubMedPubMedCentral
54.
go back to reference Medjebar S, Richard C, Fumet J-D, Malo J, Elkrief A, Blais N, Tehfe M, Florescu M, Boidot R, Truntzer C, Routy B, Ghiringhelli F. Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers. J Clin Oncol. 2019;37(15):e20512. Medjebar S, Richard C, Fumet J-D, Malo J, Elkrief A, Blais N, Tehfe M, Florescu M, Boidot R, Truntzer C, Routy B, Ghiringhelli F. Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers. J Clin Oncol. 2019;37(15):e20512.
55.
go back to reference Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet J-D, Richard C, Elkrief A, Routy B, Rebe C, Ghiringhelli F. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. Oncoimmunology. 2020;9(1):1836766.PubMedPubMedCentral Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet J-D, Richard C, Elkrief A, Routy B, Rebe C, Ghiringhelli F. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. Oncoimmunology. 2020;9(1):1836766.PubMedPubMedCentral
56.
go back to reference Drobni ZD, Michielin O, Quinaglia T, Zlotoff DA, Zubiri L, Gilman HK, Supraja S, Merkely B, Muller V, Sullivan RJ, Reynolds KL, Pittet MJ, Jain RK, Neilan TG. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022;163:108–18.PubMedPubMedCentral Drobni ZD, Michielin O, Quinaglia T, Zlotoff DA, Zubiri L, Gilman HK, Supraja S, Merkely B, Muller V, Sullivan RJ, Reynolds KL, Pittet MJ, Jain RK, Neilan TG. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022;163:108–18.PubMedPubMedCentral
57.
go back to reference Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M. Impact of renin-angiotensin system inhibitors on the efficacy of anti-PD-1/PD-L1 antibodies in NSCLC patients. Anticancer Res. 2021;41(4):2093–100.PubMed Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M. Impact of renin-angiotensin system inhibitors on the efficacy of anti-PD-1/PD-L1 antibodies in NSCLC patients. Anticancer Res. 2021;41(4):2093–100.PubMed
58.
go back to reference Cole TJ, Short KL, Hooper SB. The science of steroids. Semin Fetal Neonatal Med. 2019;24(3):170–5.PubMed Cole TJ, Short KL, Hooper SB. The science of steroids. Semin Fetal Neonatal Med. 2019;24(3):170–5.PubMed
59.
go back to reference Flammer JR, Rogatsky I. Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol (Baltimore, MD). 2011;25(7):1075–86. Flammer JR, Rogatsky I. Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol (Baltimore, MD). 2011;25(7):1075–86.
60.
go back to reference Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872.PubMed Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872.PubMed
61.
go back to reference Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Shinomiya S, Imai H, Kobayashi K, Kagamu H. Effect of systemic steroid use for immune-related adverse events in patients with non-small cell lung cancer receiving PD-1 blockade drugs. J Clin Med. 2021;10(16):3744.PubMedPubMedCentral Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Shinomiya S, Imai H, Kobayashi K, Kagamu H. Effect of systemic steroid use for immune-related adverse events in patients with non-small cell lung cancer receiving PD-1 blockade drugs. J Clin Med. 2021;10(16):3744.PubMedPubMedCentral
62.
go back to reference Drakaki A, Dhillon PK, Wakelee H, Chui SY, Shim J, Kent M, Degaonkar V, Hoang T, McNally V, Luhn P, Gutzmer R. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. Oncoimmunology. 2020;9(1):1824645.PubMedPubMedCentral Drakaki A, Dhillon PK, Wakelee H, Chui SY, Shim J, Kent M, Degaonkar V, Hoang T, McNally V, Luhn P, Gutzmer R. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. Oncoimmunology. 2020;9(1):1824645.PubMedPubMedCentral
63.
go back to reference Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy. Clin Lung Cancer. 2021;22(2):e180–92.PubMed Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy. Clin Lung Cancer. 2021;22(2):e180–92.PubMed
64.
go back to reference Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019;37(22):1927.PubMed Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019;37(22):1927.PubMed
65.
go back to reference De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, Riudavets M, Caramella C, Martinez G, Benitez JC, Martin-Romano P, El-Amarti L, Hendriks L, Ferrara R, Naltet C, Lavaud P, Gazzah A, Adam J, Planchard D, Chaput N, Besse B. Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI). Cancers. 2020;12(10):2087. De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, Riudavets M, Caramella C, Martinez G, Benitez JC, Martin-Romano P, El-Amarti L, Hendriks L, Ferrara R, Naltet C, Lavaud P, Gazzah A, Adam J, Planchard D, Chaput N, Besse B. Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI). Cancers. 2020;12(10):2087.
66.
go back to reference Skribek M, Rounis K, Afshar S, Grundberg O, Friesland S, Tsakonas G, Ekman S, De Petris L. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer. 2021;145:245–54.PubMed Skribek M, Rounis K, Afshar S, Grundberg O, Friesland S, Tsakonas G, Ekman S, De Petris L. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer. 2021;145:245–54.PubMed
67.
go back to reference Sorial MN, Huynh JP, Azzoli CG, Liauw JC, Brunault RD, Collins CM, Zullo AR. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. Eur J Cancer. 2021;145:234–44.PubMedPubMedCentral Sorial MN, Huynh JP, Azzoli CG, Liauw JC, Brunault RD, Collins CM, Zullo AR. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. Eur J Cancer. 2021;145:234–44.PubMedPubMedCentral
68.
go back to reference Huang DD-R, Liao B-C, Hsu W-H, Yang C-Y, Lin Y-T, Wu S-G, Tsai T-H, Chen K-Y, Ho C-C, Liao W-Y, Shih J-Y, Yu C-J, Yang JC-H, Cheng A-L, Shen Y-C. Effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors. Oncology. 2023;102:318–26.PubMed Huang DD-R, Liao B-C, Hsu W-H, Yang C-Y, Lin Y-T, Wu S-G, Tsai T-H, Chen K-Y, Ho C-C, Liao W-Y, Shih J-Y, Yu C-J, Yang JC-H, Cheng A-L, Shen Y-C. Effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors. Oncology. 2023;102:318–26.PubMed
69.
go back to reference Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18:1–11. Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18:1–11.
70.
go back to reference Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017;36:1–13. Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017;36:1–13.
71.
go back to reference Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052–62.PubMedPubMedCentral Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052–62.PubMedPubMedCentral
72.
go back to reference Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF. Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther. 2016;158:24–40.PubMed Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF. Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther. 2016;158:24–40.PubMed
73.
go back to reference Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. 2022;39(1):58–74.PubMed Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. 2022;39(1):58–74.PubMed
74.
go back to reference Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139–46.PubMed Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139–46.PubMed
75.
go back to reference Li Y, Du Y, Sun T, Xue HD, Jin ZY, Tian J. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. BMC Cancer. 2018;18:1–7. Li Y, Du Y, Sun T, Xue HD, Jin ZY, Tian J. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. BMC Cancer. 2018;18:1–7.
76.
go back to reference Li HS, Xu H, Duan J, Wang Z, Zhong J, Cui YY, Fang Q, Lei SY, Wang Y. DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: a prospective, single-arm, phase II trial (DEMAIN). Ann Oncol. 2023;34:S806. Li HS, Xu H, Duan J, Wang Z, Zhong J, Cui YY, Fang Q, Lei SY, Wang Y. DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: a prospective, single-arm, phase II trial (DEMAIN). Ann Oncol. 2023;34:S806.
77.
go back to reference Bongiovanni A, Foca F, Menis J, Stucci SL, Artioli F, Guadalupi V, Forcignano MR, Fantini M, Recine F, Mercatali L, Spadazzi C, Burgio MA, Fausti V, Miserocchi A, Ibrahim T. Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio. Front Immunol. 2021;12:697298.PubMedPubMedCentral Bongiovanni A, Foca F, Menis J, Stucci SL, Artioli F, Guadalupi V, Forcignano MR, Fantini M, Recine F, Mercatali L, Spadazzi C, Burgio MA, Fausti V, Miserocchi A, Ibrahim T. Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio. Front Immunol. 2021;12:697298.PubMedPubMedCentral
78.
go back to reference Cao Y, Afzal MZ, Shirai KJJOTD. Does denosumab offer survival benefits?—Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. J Thoracic Dis. 2021;13(8):4668–77. Cao Y, Afzal MZ, Shirai KJJOTD. Does denosumab offer survival benefits?—Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. J Thoracic Dis. 2021;13(8):4668–77.
79.
go back to reference Zhu Y-J, Chang X-S, Zhou R, Chen Y-D, Ma H-C, Xiao Z-Z, Qu X, Liu Y-H, Liu L-R, Li Y, Yu Y-Y, Zhang H-B. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold” immune characteristics in Non-small cell lung cancer. Lung Cancer. 2022;166:189–96.PubMed Zhu Y-J, Chang X-S, Zhou R, Chen Y-D, Ma H-C, Xiao Z-Z, Qu X, Liu Y-H, Liu L-R, Li Y, Yu Y-Y, Zhang H-B. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold” immune characteristics in Non-small cell lung cancer. Lung Cancer. 2022;166:189–96.PubMed
80.
go back to reference Qiang HP, Lei YQ, Shen YC, Li JQ, Zhong H, Zhong RB, Zhang XY, Chang Q, Lu JH, Feng H, Zhu Y, Addeo A, Banna GL, Oh IJ, Qian JL, Chu TQ. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res. 2022;11(1):87–99.PubMedPubMedCentral Qiang HP, Lei YQ, Shen YC, Li JQ, Zhong H, Zhong RB, Zhang XY, Chang Q, Lu JH, Feng H, Zhu Y, Addeo A, Banna GL, Oh IJ, Qian JL, Chu TQ. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res. 2022;11(1):87–99.PubMedPubMedCentral
81.
go back to reference Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Saito S, Sone T, Kasahara K, Tsuchiya H. The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer. Front Oncol. 2022;12:871675.PubMedPubMedCentral Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Saito S, Sone T, Kasahara K, Tsuchiya H. The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer. Front Oncol. 2022;12:871675.PubMedPubMedCentral
82.
go back to reference Montinari MR, Minelli S, Caterina RD. The first 3500 years of aspirin history from its roots—a concise summary. Vascul Pharmacol. 2019;113:1–8.PubMed Montinari MR, Minelli S, Caterina RD. The first 3500 years of aspirin history from its roots—a concise summary. Vascul Pharmacol. 2019;113:1–8.PubMed
83.
go back to reference Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114147.PubMedPubMedCentral Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114147.PubMedPubMedCentral
84.
go back to reference Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem. 2012;11:52–64.PubMed Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem. 2012;11:52–64.PubMed
86.
go back to reference Lee C, Ramirez JA, Guitart J, Diaz LK. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutaneous Pathol. 2008;35(11):989–94. Lee C, Ramirez JA, Guitart J, Diaz LK. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutaneous Pathol. 2008;35(11):989–94.
87.
go back to reference Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Can Res. 2017;77(3):790–801. Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Can Res. 2017;77(3):790–801.
88.
go back to reference Uddin S, Ahmed M, Hussain A. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Cancer Cell Biol. 2009;126(2):382–94. Uddin S, Ahmed M, Hussain A. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Cancer Cell Biol. 2009;126(2):382–94.
89.
go back to reference Zhang HY, Lu JP, Jiao Y, Chen Q, Li M, Wang ZC, Yu ZD, Huang XD, Yao A, Gao Q, Xie WG, Li L, Yao P. Aspirin inhibits natural killer/T-cell lymphoma by modulation of VEGF expression and mitochondrial function. Front Oncol. 2019;8:679.PubMedPubMedCentral Zhang HY, Lu JP, Jiao Y, Chen Q, Li M, Wang ZC, Yu ZD, Huang XD, Yao A, Gao Q, Xie WG, Li L, Yao P. Aspirin inhibits natural killer/T-cell lymphoma by modulation of VEGF expression and mitochondrial function. Front Oncol. 2019;8:679.PubMedPubMedCentral
90.
go back to reference Pan M-R, Chang H-C, Hung W-C. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal. 2008;20(6):1134–41.PubMed Pan M-R, Chang H-C, Hung W-C. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal. 2008;20(6):1134–41.PubMed
91.
go back to reference Dub C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code CC, Sampson M, Moher DJAOIM. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Internal Med. 2007;146:365–75. Dub C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code CC, Sampson M, Moher DJAOIM. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Internal Med. 2007;146:365–75.
92.
go back to reference Aiad M, Tahir A, Fresco K, Prenatt Z, Ramos-Feliciano K, Walia J, Stoltzfus J, Albandar HJ. Does the combined use of aspirin and immunotherapy result in better outcomes in non-small cell lung cancer than immunotherapy alone? Cureus. 2022;14(6): e25891.PubMedPubMedCentral Aiad M, Tahir A, Fresco K, Prenatt Z, Ramos-Feliciano K, Walia J, Stoltzfus J, Albandar HJ. Does the combined use of aspirin and immunotherapy result in better outcomes in non-small cell lung cancer than immunotherapy alone? Cureus. 2022;14(6): e25891.PubMedPubMedCentral
93.
go back to reference Moghanaki D, Stokes WA, Behera M, Jiang R, Gutman D, Giuste F, Burns A, Sebastian N, Ramalingam S, Sukhatme V, Lowe MC, Ramalingam SS, Sukhatme V. Association of concomitant NSAID and immunotherapy on outcomes in patients with non-small cell lung cancer: analysis of the National Veterans Health Administration Database. J Clin Oncol. 2021;39(15_suppl):9107–9107. Moghanaki D, Stokes WA, Behera M, Jiang R, Gutman D, Giuste F, Burns A, Sebastian N, Ramalingam S, Sukhatme V, Lowe MC, Ramalingam SS, Sukhatme V. Association of concomitant NSAID and immunotherapy on outcomes in patients with non-small cell lung cancer: analysis of the National Veterans Health Administration Database. J Clin Oncol. 2021;39(15_suppl):9107–9107.
94.
go back to reference Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, Crayton SH, Silk AW, Nosher JL, Gentile MA, Mehnert JM, Jabbour SK. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. J Immunother Cancer. 2020;8(2):e000889.PubMedPubMedCentral Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, Crayton SH, Silk AW, Nosher JL, Gentile MA, Mehnert JM, Jabbour SK. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. J Immunother Cancer. 2020;8(2):e000889.PubMedPubMedCentral
95.
go back to reference Kanai O, Ito T, Saito Z, Yamamoto Y, Fujita K, Okamura M, Hashimoto M, Nakatani K, Sawai S, Mio T. Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer. Thoracic Cancer. 2021;12(6):949–57.PubMedPubMedCentral Kanai O, Ito T, Saito Z, Yamamoto Y, Fujita K, Okamura M, Hashimoto M, Nakatani K, Sawai S, Mio T. Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer. Thoracic Cancer. 2021;12(6):949–57.PubMedPubMedCentral
96.
go back to reference Nelli F, Virtuoso A, Giannarelli D, Fabbri A, Berrios JRG, Marrucci E, Fiore C, Ruggeri EM. Effects of acetaminophen exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small-cell lung cancer: a propensity score-matched analysis. Curr Oncol. 2023;30(9):8117–33.PubMedPubMedCentral Nelli F, Virtuoso A, Giannarelli D, Fabbri A, Berrios JRG, Marrucci E, Fiore C, Ruggeri EM. Effects of acetaminophen exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small-cell lung cancer: a propensity score-matched analysis. Curr Oncol. 2023;30(9):8117–33.PubMedPubMedCentral
97.
go back to reference Zhang H. Cancer pain management—new therapies. Curr Oncol Rep. 2022;24(2):223–6.PubMed Zhang H. Cancer pain management—new therapies. Curr Oncol Rep. 2022;24(2):223–6.PubMed
98.
go back to reference Pergolizzi JV, LeQuang JA, Berger GK, Raffa RB. The basic pharmacology of opioids informs the opioid discourse about misuse and abuse: a review. Pain Ther. 2017;6(1):1–16.PubMedPubMedCentral Pergolizzi JV, LeQuang JA, Berger GK, Raffa RB. The basic pharmacology of opioids informs the opioid discourse about misuse and abuse: a review. Pain Ther. 2017;6(1):1–16.PubMedPubMedCentral
99.
go back to reference Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book. 2015;35:e593–9. Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book. 2015;35:e593–9.
100.
go back to reference Malafoglia V, Ilari S, Vitiello L, Tenti M, Balzani E, Muscoli C, Raffaeli W, Bonci A. The interplay between chronic pain, opioids, and the immune system. Neuroscientist. 2022;28(6):613–27.PubMed Malafoglia V, Ilari S, Vitiello L, Tenti M, Balzani E, Muscoli C, Raffaeli W, Bonci A. The interplay between chronic pain, opioids, and the immune system. Neuroscientist. 2022;28(6):613–27.PubMed
101.
go back to reference Zhang H, Zhou D, Gu J, Qu M, Guo K, Chen W, Miao C. Targeting the mu-opioid receptor for cancer treatment. Curr Oncol Rep. 2021;23(10):111.PubMed Zhang H, Zhou D, Gu J, Qu M, Guo K, Chen W, Miao C. Targeting the mu-opioid receptor for cancer treatment. Curr Oncol Rep. 2021;23(10):111.PubMed
102.
go back to reference Yu XY, Zhao L, Song B. Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population. BMC Pulmonary Med. 2022;22(1):431. Yu XY, Zhao L, Song B. Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population. BMC Pulmonary Med. 2022;22(1):431.
103.
go back to reference Hasegawa T, Oguri T, Osawa T, Sawa T, Osaga S, Okuyama T, Uchida M, Maeno K, Fukuda S, Nishie H, Niimi A, Akechi T. Opioid dose and survival of patients with incurable nonsmall cell lung cancer: a prospective cohort study. J Palliat Med. 2018;21(10):1436–41.PubMed Hasegawa T, Oguri T, Osawa T, Sawa T, Osaga S, Okuyama T, Uchida M, Maeno K, Fukuda S, Nishie H, Niimi A, Akechi T. Opioid dose and survival of patients with incurable nonsmall cell lung cancer: a prospective cohort study. J Palliat Med. 2018;21(10):1436–41.PubMed
104.
go back to reference Young P, Elghawy O, Mock J, Wynter E, Gentzler RD, Martin LW, Novicoff W, Hall R. Impact of opioid use on duration of therapy and overall survival for patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Curr Oncol. 2024;31(1):260–73.PubMedPubMedCentral Young P, Elghawy O, Mock J, Wynter E, Gentzler RD, Martin LW, Novicoff W, Hall R. Impact of opioid use on duration of therapy and overall survival for patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Curr Oncol. 2024;31(1):260–73.PubMedPubMedCentral
105.
go back to reference Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–8.PubMed Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–8.PubMed
106.
go back to reference Collison J. Checkpoint inhibitor-induced arthritis is persistent. Nat Rev Rheumatol. 2019;15(12):698–698.PubMed Collison J. Checkpoint inhibitor-induced arthritis is persistent. Nat Rev Rheumatol. 2019;15(12):698–698.PubMed
107.
go back to reference Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP, Ghosh N, Rajesh D, Aude CA, Gedmintas L, MacFarlane L, Arabelovic S, Falohun A, Mushtaq K, Haj FA, Diab A, Shah AA, Bingham CO, Chan KK, Cappelli LC. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023;82(7):920–6.PubMed Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP, Ghosh N, Rajesh D, Aude CA, Gedmintas L, MacFarlane L, Arabelovic S, Falohun A, Mushtaq K, Haj FA, Diab A, Shah AA, Bingham CO, Chan KK, Cappelli LC. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023;82(7):920–6.PubMed
108.
go back to reference Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, Sakagami T. Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res. 2020;8(10):1236–42.PubMed Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, Sakagami T. Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res. 2020;8(10):1236–42.PubMed
109.
go back to reference Chen MT, Ma LL, Yu HQ, Huang SY, Zhang JH, Gong J, Yang LJ, Chen L, Luo HJ, Tian L, Wang SX. JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China. Front Oncol. 2023;13:1155592.PubMedPubMedCentral Chen MT, Ma LL, Yu HQ, Huang SY, Zhang JH, Gong J, Yang LJ, Chen L, Luo HJ, Tian L, Wang SX. JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China. Front Oncol. 2023;13:1155592.PubMedPubMedCentral
110.
go back to reference Yu H, Chen M. Gut microbiota mediates the protective effects of postbiotics attenuating the immune-related adverse events in non-small-cell lung cancer patients: a randomized, controlled trial in Chongqing, China. Ann Oncol. 2023;34:S832. Yu H, Chen M. Gut microbiota mediates the protective effects of postbiotics attenuating the immune-related adverse events in non-small-cell lung cancer patients: a randomized, controlled trial in Chongqing, China. Ann Oncol. 2023;34:S832.
111.
go back to reference Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260–8.PubMed Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260–8.PubMed
112.
go back to reference Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. OncoImmunology. 2018;7(6): e1434468.PubMedPubMedCentral Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. OncoImmunology. 2018;7(6): e1434468.PubMedPubMedCentral
113.
go back to reference Chancellor WZ, Mehaffey JH, Desai RP, Beller J, Balkrishnan R, Walters DM, Martin LW. Prolonged opioid use associated with reduced survival after lung cancer resection. Ann Thorac Surg. 2021;111(6):1791–8.PubMed Chancellor WZ, Mehaffey JH, Desai RP, Beller J, Balkrishnan R, Walters DM, Martin LW. Prolonged opioid use associated with reduced survival after lung cancer resection. Ann Thorac Surg. 2021;111(6):1791–8.PubMed
114.
go back to reference Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113:i109–16.PubMedPubMedCentral Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113:i109–16.PubMedPubMedCentral
115.
go back to reference Prasetya RA, Metselaar-Albers M, Engels F. Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: a pharmacodynamics perspective. Eur J Pharmacol. 2021;906:174284.PubMed Prasetya RA, Metselaar-Albers M, Engels F. Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: a pharmacodynamics perspective. Eur J Pharmacol. 2021;906:174284.PubMed
116.
go back to reference Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014;113:103–8. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014;113:103–8.
117.
go back to reference Fujioka N, Nguyen J, Chen CS, Li YF, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg. 2011;113(6):1353–64.PubMedPubMedCentral Fujioka N, Nguyen J, Chen CS, Li YF, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg. 2011;113(6):1353–64.PubMedPubMedCentral
118.
go back to reference Fatehi Hassanabad A, MacQueen KT. Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer. Cell Oncol. 2021;44(1):1–18. Fatehi Hassanabad A, MacQueen KT. Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer. Cell Oncol. 2021;44(1):1–18.
119.
go back to reference Wang Y, Hu Y, Wang T, Che G, Li L. Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents. Front Pharmacol. 2023;14:1123834.PubMedPubMedCentral Wang Y, Hu Y, Wang T, Che G, Li L. Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents. Front Pharmacol. 2023;14:1123834.PubMedPubMedCentral
Metadata
Title
Concomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review
Authors
Han Deng
Junxiang Zhou
Zhixi Liu
Lu Huang
Yanru Gu
Peng Chen
Hongtao Xiao
Publication date
01-02-2025
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2025
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02591-3

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now